Aeglea BioTherapeutics to Host Conference Call to Report Phase 3 Topline Results of Pegzilarginase in Patients with Arginase 1 Deficiency
Aeglea BioTherapeutics (NASDAQ: AGLE) will hold an investor conference call on December 6, 2021, at 8:00 AM ET to discuss topline results from the PEACE Phase 3 clinical trial of pegzilarginase for treating Arginase 1 Deficiency (ARG1-D). The company is focused on developing innovative enzyme therapeutics for rare metabolic diseases. Pegzilarginase has received both Rare Pediatric Disease and Breakthrough Therapy Designations.
- Pegzilarginase has received Rare Pediatric Disease and Breakthrough Therapy Designations.
- Ongoing Phase 3 pivotal trial for pegzilarginase shows potential for significant market impact.
- None.
AUSTIN, Texas, Dec. 5, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that it will host an investor conference call and webcast tomorrow morning to discuss the topline results from the PEACE Phase 3 clinical trial of pegzilarginase in patients with Arginase 1 Deficiency (ARG1-D).
Investors and the public are invited to listen to a live audio webcast of the conference call on December 6, 2021, at 8:00am ET, which can be accessed prior to the start of the call by dialing 1-877-425-9470 (U.S.) or 1-201-389-0878 (International) Conference ID 13725511 or through the Events & Presentations section of the Company's website.
About Aeglea BioTherapeutics
Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare metabolic diseases with limited treatment options. Aeglea's lead product candidate, pegzilarginase, is in an ongoing Phase 3 pivotal trial in patients with Arginase 1 Deficiency and has received both Rare Pediatric Disease and Breakthrough Therapy Designations. Aeglea has an ongoing Phase 1/2 clinical trial of AGLE-177 for the treatment of Homocystinuria. AGLE-177 has been granted Rare Pediatric Disease Designation. Aeglea has an active discovery platform focused on engineering small changes in human enzymes to have a big impact on the lives of patients and their families. For more information, please visit http://aeglea.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/aeglea-biotherapeutics-to-host-conference-call-to-report-phase-3-topline-results-of-pegzilarginase-in-patients-with-arginase-1-deficiency-301437580.html
SOURCE Aeglea BioTherapeutics, Inc.
FAQ
What is the purpose of the PEACE Phase 3 trial for AGLE?
When will Aeglea BioTherapeutics announce the results of the PEACE trial?
What designations has pegzilarginase received?
What is the stock symbol for Aeglea BioTherapeutics?
